SZSE accepts *ST Tianmao's application for voluntary delisting

Hubei Biocause Pharmaceutical, also known as *ST Tianmao, has officially had its application for the voluntary termination of listing of its A-shares on the Shenzhen Stock Exchange (SZSE) accepted. The company received formal notification from the SZSE on September 10, 2025, following the submission of its application on September 4, 2025. This decision to delist was approved by the company's first extraordinary general meeting of shareholders on August 25, 2025.

Following the delisting, *ST Tianmao plans to transfer its shares to the delisted板块 for trading, managed by the National Equities Exchange and Quotations (NEEQ). The SZSE Listing Committee will form an opinion within fifteen trading days of accepting the application, after which the SZSE will make a final decision. The company may be required to provide additional materials during this period.

*ST Tianmao's voluntary termination of listing does not include a delisting整理期. Once the SZSE announces its decision to terminate the listing, the company's shares will be delisted within five trading days. Investors are advised to pay close attention to the investment risks.